GPT and metabolic dysfunction-associated steatohepatitis: The North American guidelines (NASPGHAN) suggest performing a liver biopsy in patients with increased risk of NASH and/or advanced fibrosis such as those with high ALT levels (> 80 U/L), splenomegaly, or an aspartate aminotransferase (AST) to ALT ratio of > 1 [58].